#ORPH Open Orphan – Imutex Vaccine Phase I Study Results

AGS-v PLUS mosquito vaccine candidate shows favourable safety, tolerability, and immunogenicity results Results to be presented at the American Society of Tropical Medicine and Hygiene Annual Meeting   Open Orphan plc (AIM: ORPH) announces that data from the first-in-human Phase I clinical study evaluating the safety, immunogenicity, and in vitro efficacy of AGS-v PLUS,  Imutex Limited’s (“Imutex’) mosquito saliva […]

Open Orphan PLC #ORPH – Result of General Meeting

Result of General Meeting Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , announces that all resolutions proposed at the General Meeting held earlier today were duly passed. Further announcements regarding the proposed Distribution in Specie will […]

Open Orphan #ORPH – Major New Contract Win for Venn Life Sciences

Open Orphan plc (ORPH) a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models, is pleased to announce that it has signed a major contract with a leading vaccine developer and one of the top pharmaceutical companies in the world. […]